Part B of the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Public Law 111-87) provides grants to States and U.S. Territories to improve the quality, availability, and organization of HIV/AIDS health care and support services. Part B grants include a base grant; the AIDS Drug Assistance Program (ADAP) award; ADAP Supplemental Drug Treatment Program funds; and supplemental grants to States with "emerging communities," defined as jurisdictions reporting between 500 and 999 cumulative AIDS cases over the most recent 5 years.
All 50 States, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and the five U.S. Pacific Territories or Associated Jurisdictions are eligible for funding. Emerging Communities are defined as those reporting between 500 and 999 cumulative reported AIDS cases over the most recent 5 years.
ADAP provides medications for the treatment of HIV disease. Program funds may also be used to purchase health insurance for eligible clients and for services that enhance access to, adherence to, and monitoring of drug treatments.
Each grantee establishes its own ADAP eligibility criteria. All grantees, however, are required to implement an ADAP recertification process every 6 months to ensure that only eligible clients are served. All grantees require that program participants document their HIV status, and nine programs require a CD4 count of 500 or less. Fifteen States have established income eligibility at 200 percent or less of the Federal Poverty Level (FPL).
The ADAP in each State and Territory is unique in that it decides which medications will be included in its formulary and how those medications will be distributed. However, current legislation requires that each grantee must cover all classes of approved HIV antiretrovirals on their ADAP formulary.
Grants are awarded to all 50 States, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and a few Pacific jurisdictions.
Pressure on ADAP resources has increased substantially:
Part B grew into the largest component of the Ryan White HIVAIDS Program primarily as a result of increases in funds to support access to drug therapies.
As a result of the dramatic increase in the cost of pharmaceutical treatment and the growing number of people living with HIV/AIDS, the ADAP earmark is now the largest portion of Part B spending. The earmark has grown from $52 million in 1996 to $835 million appropriated for FY 2010. Total ADAP spending is even higher, however, because State ADAPs also receive money from their respective States, from other Ryan White HIV/AIDS Program components, and through cost-saving strategies.
Approximately 175,194 people received medications through ADAP in calendar year 2008, a 6.9 percent increase over the163,925 people served the previous year. None had adequate health insurance or the financial resources necessary to cover the cost of medications.
Many clients are enrolled in ADAP only temporarily while they await acceptance into other insurance programs, such as Medicaid. On average, 73,000 clients are served each month.
In FY 2008, 83 percent of ADAP clients have annual household incomes below 200 percent of FPL.
Of the 2,157 providers submitting data to HAB for 2008: 1,213 received Part A funds; 1,160 received Part B funds; 444 received Part C funds; and 263 received Part D funds.
Part B - ADAP Publications
Part B: States and U.S. Territories Program Fact Sheet (PDF - 221 KB)